Nuvalent, Inc.

General Information
Business:

We are a preclinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. We focus our discovery efforts on small molecule inhibitors of kinases, a class of cellular targets that can play a central role in cancer growth and proliferation. 

By prioritizing target selectivity, we believe our drug candidates have the potential to overcome resistance, minimize adverse events, optimize brain penetrance to address brain metastases, and drive more durable responses. We are advancing a robust pipeline of product candidates with parallel lead programs in cancers driven by genomic alterations in the ROS1 and ALK kinases (i.e., ROS1-positive and ALK-positive, respectively), along with multiple discovery-stage research programs. All of our programs are currently preclinical, and we plan to initiate our first clinical trial in the second half of 2021.

Our first lead product candidate, NVL-520, is a brain-penetrant ROS1-selective inhibitor, designed to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations (“wild-type ROS1”) and also remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors. We have submitted an IND for NVL-520 and the FDA has confirmed that clinical investigation of NVL-520 may proceed. We plan to initiate a first-in-human clinical trial investigating NVL-520 in ROS1-positive non-small cell lung cancer (“NSCLC”) and other advanced solid tumors in the second half of 2021.

Industry: PHARMACEUTICAL PREPARATIONS
Employees: 27
Founded: 2017
Contact Information
Address One Broadway, 14th Floor Cambridge, MA 02142
Phone Number (857) 357-7000
Web Address http://www.nuvalent.com
View Prospectus: Nuvalent, Inc.
Financial Information
Market Cap $781.66mil
Revenues $0 mil (last 12 months)
Net Income $-15.99 mil (last 12 months)
IPO Profile
Symbol NUVL
Exchange NASDAQ
Shares (millions): 9.8
Price range $17.00 - $17.00
Est. $ Volume $165.8 mil
Manager / Joint Managers J.P. Morgan/ Cowen/ Piper Sandler
CO-Managers -
Expected To Trade: 7/29/2021
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change